Home > Focus Areas > DLBCL Connect > Post
  • Saved

May 31, 2021

Lenalidomide in DLBCL: are we past the cell of origin? - PubMed

Lenalidomide in DLBCL: are we past the cell of origin? - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33989279/

Single-agent lenalidomide has modest activity in diffuse large B-cell lymphoma (DLBCL) and is thought to be more potent in activated B-cell (ABC) lymphomas, which are more treatment-resistant. However, the addition of lenalidomide to rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre ...

  • May 31, 2021
    A nice review on an important drug in Dlbcl in spite of some negative trials. The ability of this agent to induce and maintain very prolonged responses makes it a very valuable agent for a subset of these patients